March 29, 2002
Gilead Announces Changes to Senior Management Team; Organization Positioned for Continued Growth
As part of the restructuring, Gilead has combined responsibility for the corporate functions that support the strategic, financial, communications and technological planning into a broadened senior management role. As such, the Corporate Development, Finance, Corporate Communications and Information Technology groups will be centralized under the leadership of John F. Milligan, PhD, who has been promoted to Senior Vice President and Chief Financial Officer, reporting directly to the CEO. Dr. Milligan joined Gilead in 1990, serving most recently as Vice President, Corporate Development. In addition, Dr. Milligan has been leading the company's annual Portfolio Review and Strategic Planning process and supervising the Corporate Communications and Investor Relations function. Sharon Surrey-Barbari, who joined Gilead in 1998 and has served as the company's Vice President and Chief Financial Officer since February 2000, has announced her resignation from Gilead. Ms. Surrey-Barbari will remain at the company for several months to facilitate a smooth transition of management of the Gilead U.S. and European financial groups.
In addition, Gilead has completed organizational changes that will best position the company to achieve its goals. With the growing importance of the company's commercial function, the Manufacturing group in San Dimas will be more closely aligned with other operational areas, reporting to Mark L. Perry, Executive Vice President, Operations. Gilead also has established a Paris, France headquarters for its European operations. A new position of Vice President, European Operations is expected to be filled in the coming months. Following the divestiture of Gilead's Boulder operations, the Research and Development group has been reorganized to ensure seamless integration of all groups and functions. This group continues to be led by Norbert Bischofberger, PhD, Executive Vice President, Research and Development.
"This is a remarkable time for our company, and Gilead has a tremendous team in place that is devoted to providing novel therapeutics for people facing life-threatening infectious diseases," said John C. Martin, PhD, President and Chief Executive Officer, Gilead. "John Milligan's contributions to Gilead over the past 12 years have been significant, and I look forward to the expanded role he will play leading our company toward profitability and continued growth.
"I would like to join my colleagues in thanking Sharon for her contributions to Gilead over the past several years," Dr. Martin continued. "Sharon's expertise has been invaluable through our merger with NeXstar, the divestiture of our oncology assets to OSI and many other significant milestones for the company."
For more information on Gilead Sciences, please visit the company's web site at www.gilead.com or call the Gilead Corporate Communications Department at 1-800-GILEAD-5 or 1-650-574-3000.
CONTACT: Gilead Sciences Sheryl Meredith, 650/522-5505 (Investors) Amy Flood, 650/522-5643 (Media) URL: http://www.businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.